The gap, named
The priced page carries one figure, labelled compounded GLP-1, with a monthly period attached. A customer quotation on the same page describes paying the same flat amount every month, which is useful corroboration that the figure is real and recurring.
What no sentence on that page does is say which drug it buys. Semaglutide and tirzepatide are different molecules with different published prices everywhere else in this comparison, and a single figure covering both without saying which is not a price a reader can compare.
This roster records that honestly rather than tidily. The compound field says the molecule is unspecified and the qualifier says the seller names no drug beside the figure. Filling it in from the site's other prose would have been this site inventing a fact the seller declined to state.
The three prices that are in the file and not on the screen
The homepage's served markup contains drug-specific price cards — a figure for compounded semaglutide, one for compounded tirzepatide and one for a brand-name product. None of them renders.
That was measured rather than assumed. The page's visible text is the same length before and after every control on it is operated, and contains none of those strings. A tag-stripping fetch of the same page reports three prices the site does not publish.
So they are not quoted here, and they should not be quoted anywhere. This is the exact failure mode where a review ends up citing a table that renders nowhere, and the rule that prevents it is short: visible text or it is not published.
The warning letter, stated plainly
Sprout Health Partners received warning letter number 715879, issued in September 2025 by the agency's drug centre, over the unlawful sale of unapproved and misbranded drugs. The letter names the company's own domain and quotes one claim from the site: that GLP-1 medications are FDA-approved and backed by extensive clinical research.
A warning letter is a disclosure, not a finding of guilt, and it is not treated here as a reason to exclude a company or to score it down. Five of the sixty-five sellers here carry one. The number, the date and a link to the agency's own text are on this row.
And the measured third fact: the flagged phrase is gone from the live page. The page's single remaining reference to FDA approval is the opposite of the flagged one — a disclaimer stating that compounded GLP-1 medications are not FDA-approved and have not been evaluated by the agency for safety, effectiveness or quality. The letter also happens to be the clearest public confirmation of which drugs this company sells.
What the money looks like around the edges
A first-month rate runs under a discount banner with a checkout code, and it is recorded here as an introductory offer rather than as a price. The flat monthly figure is what describes a year.
The refund policy publishes two things most sellers here leave unstated. A flat clinical review fee is retained once a provider consultation has been completed, before a prescription is sent, and the policy works through a plan-value example so a reader can see how a partial refund is calculated. That is a genuinely unusual disclosure and it is on the side of the reader.
What is not published is any statement about a membership or programme fee, in either direction, across five pages. A third-party write-up asserts that no membership, consultation or cancellation fee applies; that sentence is not on the site. Fifteen of the sixty-five sellers here are silent the same way, and silence is not an answer.
The rest of the disclosure
The corporate side is fine. The operating company is named in the terms, a street address is printed, and a governing-law clause names a state. One oddity worth saying out loud: the address is in one state and the governing-law clause names another, on opposite sides of the country.
No state list appears anywhere. The only state-shaped sentences on the site describe state-licensed pharmacies, which is a licensing statement rather than a coverage one.
No compounding pharmacy is named and no individual prescribing clinician is named. On a row where the price does not name the drug either, that is three questions a buyer has to ask a person before they can answer any of them.
Sprout Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded) | $299/moA flat monthly figure the seller attaches to no drug: "Compounded GLP-1 · Starting at $299/ month", corroborated on the same page by a customer quotation reading "I pay a flat fee of $299 each month." A lower first month runs under a discount banner and is recorded separately. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 65 providers reviewed here are paid partners today; the other 61 are not. See how this works.
See Sprout Health's current price →Good fit if
- Readers who want one flat published figure with a monthly period on it, on a page they can read without an intake.
- Buyers who want a refund policy that states what is retained and works through an example.
- People who prefer a company with a documented regulatory correction they can read in full to one with no public record either way.
- Readers willing to ask which drug a price buys before they pay for it.
Look elsewhere if
- Anyone comparing prices between molecules. This seller's figure names no drug, so it cannot be set beside a semaglutide or tirzepatide price honestly.
- Readers who will not buy from a company with an FDA enforcement history, which is a legitimate position and better taken with the letter in front of you.
- Buyers who need their state confirmed before starting, or who need a membership answered in either direction.
- People who need the compounding pharmacy or an individual prescribing clinician named.
How this review was verified
- Read the priced page in a browser and audited every dollar element for computed opacity, visibility and a real laid-out rectangle before recording a figure. The recorded figure lays out normally and is fully visible.
- Compared the homepage's served markup against its rendered visible text after operating every control on the page. The text is identical in length before and after and contains none of the three drug-specific figures the markup carries, so none of them is recorded or quoted.
- Recorded the compound as unspecified rather than inferring it. The two drugs this company sells are established from its own FAQ prose and from the agency's letter, and neither source attaches a price to a molecule.
- Read the warning letter in full from the agency's own record and logged its number, date, issuing centre, recipient and the claim it quotes.
- Censused the live priced page for the flagged phrase and found none, then opened the page's single remaining reference to FDA approval, which is a disclaimer to the opposite effect.
- Censused five pages for any membership statement in either direction and found none, and checked a third-party claim that no fees apply against the site itself, where that sentence does not appear.
- Read the agency's search results for the trading name row by row. Most belong to food producers and one to an unrelated pharmaceutical company; only one is this entity. The count is deliberately not published, because on this name a count is not an answer. That search covers warning letters only, and untitled letters were not searched.
- Began the intake and stopped two questions in. No account was created, no payment details were entered and nothing was submitted, so nothing is claimed from it — a drug-scoped price may well sit further down that funnel.